This companion diagnostic test is used to assess the mutational status of EGFR exon 19 and exon 21 to identify patients with advanced non-small-cell lung cancer (NSCLC) that are eligible for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKI). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.